Drug Type Small molecule drug |
Synonyms ODS-101, ODS101, OPM 101 + [1] |
Target |
Action inhibitors |
Mechanism RIPK2 inhibitors(Serine/threonine-protein kinase RIPK2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Locally Advanced Melanoma | Phase 2 | - | 01 Sep 2025 | |
Inflammatory Bowel Diseases | Phase 1 | France | 09 Feb 2023 | |
Cystitis, Interstitial | Phase 1 | France | - | |
Neoplasms | Phase 1 | France | - |
Not Applicable | - | - | tfegcfmopx(qjwaampgxs) = qaorlagypb kqeresweee (evaflltxev ) View more | - | 13 Oct 2024 | ||
Corporate Publications Manual | Phase 1 | - | 104 | deifxrmqfn(wimtmkkrvv) = tinwoxdacw sqpnfqycbz (bviekpngly ) View more | Positive | 16 Jul 2024 | |
Placebo | - |